文献速递基层心理健康儿童保健

青少年共病物质使用与精神障碍的药物治疗:系统综述

Pharmacotherapy interventions for adolescent co-occurring substance use and mental health disorders: a systematic review.
PubMed 文献 · Fam Pract · 2022-01-01

该系统综述汇总了常用精神科药物治疗对青少年物质使用结局影响的证据。检索五个数据库后纳入10项随机对照试验,涉及7种药物,偏倚风险低至中等。未发现药物治疗对共病物质使用产生影响的证据,提示单靠药物不足以应对共病物质使用。

要点

  • 10项RCT均未显示精神科药物改善青少年物质使用结局。
  • 多数试验同时纳入行为干预,药物单独效果难以判定。
  • 家庭医学医生处方精神药物时应预期需额外干预处理物质使用。

核心结论

  • 未发现证据表明针对共病精神障碍的药物治疗可影响青少年物质使用结局。
  • 为精神健康处方药物的家庭医学临床医生应意识到,可能还需额外干预来应对共病物质使用。

研究设计与样本

  • 系统综述,检索五个数据库,属更大范围青少年物质使用干预系统综述的一部分。
  • 由两名研究者筛选文献,提取研究设计、患者与治疗特征及结果,并完成偏倚风险分析与定性综合。
  • 纳入10项随机对照试验,探索7种药物疗法,所有研究偏倚风险为低至中等。

主要发现

  • 4项研究评估共病抑郁与物质使用的药物治疗,3项评估注意缺陷多动障碍与物质使用,3项评估双相障碍与物质使用。
  • 10项研究中有5项同时包含行为干预。
  • 未发现药物治疗对共病物质使用结局有影响的证据。

临床怎么用

  • 家庭医学临床医生为青少年精神障碍处方药物时,应预期需额外干预以处理共病物质使用。
  • 对共病物质使用与精神障碍的青少年,药物治疗不应被视为足以解决物质使用问题的单独手段。

局限性

  • 纳入研究仅10项,各精神障碍类别下研究数量有限。
  • 多数研究同时含行为干预,难以分离药物的独立效应。
  • 原文未报告所纳入研究的具体样本量、效应量及置信区间。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Co-occurring mental health and substance use (SU) disorders among adolescents are common, with two-thirds of adolescents who seek SU treatment also requiring support for mental health. Primary care physicians play a key role in the pharmacological treatment of mental health disorders among adolescents, however, little is known about the impact of these treatments on SU outcomes. OBJECTIVES: This systematic review summarizes the evidence regarding commonly used pharmacotherapy interventions for mental health and their impact on adolescent SU. METHODS: Literature searches were conducted across five databases as part of a larger systematic review of adolescent SU interventions. Studies were screened for eligibility by two researchers, and study data were extracted regarding study design, patient and treatment characteristics and results. Risk of bias analyses and qualitative syntheses were completed to evaluate the strength of the evidence and the impact of pharmacotherapy on SU outcomes. RESULTS: Ten randomized controlled trials exploring seven pharmacotherapies met criteria for inclusion. All studies had low to moderate risk of bias. Four studies evaluated pharmacotherapy for co-occurring depression and SU, three evaluated attention deficit hyperactivity disorder and SU, and three evaluated bipolar disorder and SU. Five of the 10 studies also included a behavioural intervention. We found no evidence that pharmacotherapy for co-occurring mental health diagnoses impacted SU. CONCLUSION: Family medicine clinicians prescribing pharmacotherapy for mental health should be aware that additional interventions will likely be needed to address co-occurring SU. Many adolescents have both mental health and substance use problems. Adolescents have difficulty getting effective treatment for both substance use and mental health concerns, in part because these treatments are often offered separately. Primary care physicians, who often care for adolescents with mental health concerns, may prescribe medications for diagnoses such as attention deficit hyperactivity disorder, depression or early symptoms of bipolar disorder. However, there is little research indicating whether these medications are helpful for co-occurring substance use disorder symptoms. This paper presents a review of existing research on medications used to treat common mental health disorders to evaluate their effect on substance use. Ten studies address this question and suggest that medications for mental health are insufficient for helping adolescents with substance use disorders or substance use problems.

来源:Fam Pract,查看原文。版权归原作者所有。

引用

  1. Scott K, Becker SJ, Helseth SA, et al. Pharmacotherapy interventions for adolescent co-occurring substance use and mental health disorders: a systematic review. Fam Pract. 2022. PMID: 34448853. doi:10.1093/fampra/cmab096

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。